AFLP patterns from all ESBL-E <i>E</i>. <i>coli</i>, <i>E</i>. <i>cloacae complex</i> and <i>K</i>. <i>pneumonia</i> eligible for cluster analyses.

<p>Strains clustering with a similarity between 90 and 100% were defined as identical strains. Strains clustering with a similarity above 35% were defined as different strains of the same species and strains clustering with a similarity below 35% were defined as different species. Identical strains are indicated in color. Each strain was coded with the number of the year in combination with a letter. * three ESBL positive strains cultured in a sample from patient 2012-N showed fenotypic differences. Therefore AFLP analyses was performed from all three samples.</p

ESBL prevalence over time, including bacterial species and ESBL genes.

<p>^& = Number of ESBL positive patients divided by the number of evaluable cultures (patients)</p><p>^# = Primary = patients with a unique isolates and index patients</p><p>^$ = Secondary = patients with ESBL isolates caused by nosocomial transmission</p><p>ESBL prevalence over time, including bacterial species and ESBL genes.</p

Proportion of CTX-M-1 like ESBL genes over time.

<p>The vertical bars represent the percentage of CTX-M-1 like ESBL genes divided by the total number of ESBL genes. The line represents the logarithmic trendline.</p

ESBL-E prevalence in relation with the duration of hospitalisation (patients in day-care were excluded).

<p>Vertical bars represent the 95% confidence intervals.</p

ESBL-E prevalence within the different medical specialties.

<p>^# = percentages refer to the number of ESBL-E positive patients divided by the total within medical specialty</p><p>ESBL-E prevalence within the different medical specialties.</p

Baseline characteristics of screened patients.

<p>^# = percentages refer to the number divided by the total patients with evaluable cultures</p><p>Baseline characteristics of screened patients.</p

Comparison of phenotypic pAmpC confirmation tests.

<p><i>The antibiotics used in the DDCT tests were cefotaxime and ceftazidime combined with cloxacilllin or boronic acid. Etest CN/CNI consisted of cefotetan (CN) with cefotetan-cloxacillin (CNI).</i></p><p>*DDCT with cloxacillin/boronic acid and CN/CNI Etest.</p><p>**Sensitivity and specificity of these confirmation tests is performed without ACC-1 in the analysis due to susceptibility for cefoxitin.</p